The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...
Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...
Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ...
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...
LONDON, Aug. 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology [1]. Treatment with APO-go ...
Questions about an infusion device have scuttled Supernus Pharmaceuticals’ attempt to win approval of a Parkinson’s disease therapy. The complete response letter marks the second time in two years ...
Please provide your email address to receive an email when new articles are posted on . Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback